ArticleScientific reports2025
Establishment and validation of a diagnostic model for cholangiocarcinoma based on LightGBM machine-learning algorithm.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The escalating annual death toll attributed to Cholangiocarcinoma (CCA) is, in part, a consequence of delayed diagnosis. This study developed an optimal CCA diagnostic model through the application of 11 machine-learning algorithms. Initially, 105 differentially expressed genes (DEGs) were identified by analyzing gene expression profiles from 307 CCA tumor tissues and 124 adjacent non-tumor tissues. WGCNA, F-test, characteristic importance, and Lasso regression analysis were employed to identify key DEGs, including APOF, DIO1, APOM, and OTC. Subsequently, diagnostic models were constructed based on APOF, DIO1, and OTC using 11 machine-learning algorithms. The LightGBM algorithm was determined as the optimal model through ROC curve analysis and machine learning performance evaluation, achieving an AUC of 0.84, with accuracy, precision, and recall values of 0.80, 0.83, and 0.90, respectively. Subsequent analyses included gene enrichment, protein-protein interaction (PPI), and CCA-related drug assessments. Additionally, the study revealed an imbalance in immune cell infiltration in CCA and identified CCL16 as a chemokine involved in immunoregulation. RT-qPCR confirmed that APOF, DIO1, and OTC were significantly downregulated in CCA tumor tissues. In conclusion, this research provides new directions for the diagnosis and immunotherapy of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.